Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Lineage Cell Therapeutics Inc (AMEX: LCTX) closed at $1.74 down -0.57% from its previous closing price of $1.75. In other words, the price has decreased by -$0.57 from its previous closing price. On the day, 0.82 million shares were traded. LCTX stock price reached its highest trading level at $1.81 during the session, while it also had its lowest trading level at $1.71.
Ratios:
For a deeper understanding of Lineage Cell Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5. On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 24 ’25 when DON M BAILEY bought 60,000 shares for $1.60 per share.
DON M BAILEY bought 80,000 shares of LCTX for $97,472 on Sep 10 ’25. On Jan 27 ’25, another insider, BROADWOOD PARTNERS, L.P., who serves as the Director of the company, bought 7,894,737 shares for $0.76 each. As a result, the insider paid 6,000,000 and bolstered with 49,560,992 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 400769920 and an Enterprise Value of 361660928. For the stock, the TTM Price-to-Sale (P/S) ratio is 37.04 while its Price-to-Book (P/B) ratio in mrq is 18.18. Its current Enterprise Value per Revenue stands at 33.438 whereas that against EBITDA is -18.38.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.79, which has changed by 2.0701754 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $2.09, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is 1.13%, while the 200-Day Moving Average is calculated to be 72.45%.
Shares Statistics:
For the past three months, LCTX has traded an average of 1.93M shares per day and 2966200 over the past ten days. A total of 230.33M shares are outstanding, with a floating share count of 217.51M. Insiders hold about 5.57% of the company’s shares, while institutions hold 45.00% stake in the company. Shares short for LCTX as of 1763078400 were 22579627 with a Short Ratio of 17.53, compared to 1760486400 on 31772044. Therefore, it implies a Short% of Shares Outstanding of 22579627 and a Short% of Float of 17.379998999999998.
